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ABSTRACT 
Background.  Primary Aldosteronism (PA) is due to the presence of an Aldosterone-Producing 
Adenoma (APA) in almost two thirds of the cases.  Due to the lack of a specific antibody for human 
aldosterone synthase (hCYP11B2), the functional identification of aldosterone-producing sites in 
the excised adrenal gland has not been possible thus far. To tackle this challenge we used novel 
monoclonal antibodies for hCYP11B2 and hCYP11B1 to immuno-phenotype a large series of 
adrenal glands excised from patients with PA, including APA that were diagnosed by the “four 
corners criteria” and genotyped for KCNJ5 mutations.   
Aims.  Our aims were to identify the CYP11B2 and CYP11B1 steroidogenic patterns of the PA 
adrenal glands and to investigate whether immunostaining predicts the biochemical profile and/or 
the outcome of the patients. 
Design and Method.  Double immunohistochemistry and immunofluorescence was used to detect 
CYP11B2 and CYP11B1 in the excised adrenals from PA patients.  Quantification of CYP11B2 
and CYP11B1 immuno-staining was performed using an observer-independent PC-assisted method 
specifically developed in our laboratory that takes into account the area fraction and the staining 
intensity of the markers.  The staining intensity was reported as H-score value and evaluated for 
each potential aldosterone-producing structure, including CYP11B2 positive clusters, APA and 
nodules. 
Results.  Based on the CYP11B2/CYP11B1 immunostaining of 111 excised adrenal glands from 
PA patients we could identify 5 major steroidogenic patterns (the proportion of cases shown in 
parentheses): Pattern 1: adenoma with uniform CYP11B2 staining and CYP11B1 staining outside 
the adenoma (16%); Pattern 2: adenoma with diffuse CYP11B2 staining, scattered CYP11B1 
staining and some cells co-expressing CYP11B2/CYP11B1 inside the adenoma (46%); Pattern 3: 
adenoma expressing CYP11B1 and clusters of cells CYP11B2 positive (2%); Pattern 4: no 
adenoma, multiple clusters of sub-capsular CYP11B2 cells (25%); Pattern 5: multi-nodular adrenal 
cortex, clusters of sub-capsular CYP11B2 cells (11%).  
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The rate of pattern 2 differed significantly between mutated and wild-type KCNJ5 tumors (p=.012) 
and gender (p=.005).  CYP11B2 H-score in APAs reflects aldosterone production before surgery 
(r=0.388, p=.002); by contrast, CYP11B1 did not correlate with the cortisol production.  After 
adrenalectomy, steroidogenic patterns and H-score did not predict different aldosterone values 
between the patients, but, pattern 3 was prevalently detected in patients who biochemically resolved 
the PA picture, but still present high blood pressure levels. 
Conclusions.  Analysis of the excised adrenal gland from patients who were deemed to have an 
unilateral excess aldosterone production, by using specific antibodies for human CYP11B2 and 
CYP11B1, unveiled the existence of 5 different steroidogenic patterns.  The H-score based on 
immunophenotyping which takes into account all aldosterone producing sites in the gland, 
including APA, clusters and nodules, reflected the aldosterone synthesis in the adrenal gland.   
Hence surgically-curable PA is far more heterogeneous than previously held, which challenges the 
classical notion that PA entails only APA or bilateral hyperplasia.  CYP11B2 immuno-staining is a 
promising tool for gaining better understanding in the pathophysiology of PA disease. 
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RIASSUNTO 
Background.  Nei centri di riferimento per l’ipertensione arteriosa più del 50% dei casi di 
iperaldosteronismo primario (PA) sono dovuti alla presenza di un Aldosterone-Producing Adenoma 
(APA).  La surrenectomia determina la cura dall’ipertensione e la correzione del quadro biochimico 
di PA.  La comprensione dei meccanismi che inducono lo sviluppo dell’APA è, pertanto, di 
fondamentale importanza clinica. 
La diagnosi di APA ad oggi è basata sul riconoscimento, all’interno della ghiandola surrenalica, di 
un nodulo costituito da cellule chiare, senza che si abbiano informazioni funzionali sulla produzione 
di aldosterone.  La diagnosi di APA nel surrene rimosso rimane, quindi, piuttosto incerta.  Lo 
sviluppo recente degli anticorpi monoclonali per l’aldosterone sintetasi (CYP11B2) e l’11β-
idrossilasi (CYP11B1) potrebbero permettere di localizzare le cellule responsabili dell’eccessiva 
produzione di aldosterone.   
Scopo.  Lo scopo di questo studio è stato di identificare i patterns di espressione degli enzimi 
steroidogenici CYP11B2 e CYP11B1 nella ghiandola surrenalica da pazienti con PA e indagare se 
la caratterizzazione immuno-fenotipica possa predire il profilo biochimico e/o l’outcome pressorio 
di questi pazienti. 
Metodi.  I surreni rimossi da 111 pazienti operati per PA che al cateterismo delle vene surrenaliche 
avevano mostrato eccesso di secrezione unilaterale, sono stati studiati mediante immunoistochimica 
e immunofluorescenza per CYP11B2 e CYP11B1.  L’intensità della reazione cromogenica di 
CYP11B2 e CYP11B1 è stata quantificata utilizzando una metodica sviluppata nel nostro 
laboratorio che permette di attribuire ad ogni marker analizzato, un valore numerico denominato H-
score, che è direttamente proporzionale alla percentuale di area positiva allo staining nella 
ghiandola e all’intensità di colorazione.  Tutte le strutture potenzialmente competenti alla 
produzione di aldosterone (cluster di cellule CYP11B2 positive, APA e noduli) sono state analizzate 
per il calcolo dell’ H-score corrispondente. 
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Risultati.  L’analisi immunoistochimica nei pazienti PA ha permesso di identificare 5 patterns 
steroidogenici (la percentuale dei pazienti classificati nei patterns è espressa tra parentesi): pattern 1 
comprendeva i surreni con un unico adenoma compatto e positivo per CYP11B2 e cellule positive 
per CYP11B1 nel tessuto adiacente all’adenoma (16%); nel pattern 2 sono stati classificati gli 
adenomi composti da cellule positive per CYP11B2 o CYP11B1 e alcune cellule che esprimevano 
contemporaneamente CYP11B2 e CYP11B1 (46%); i surreni classificati come pattern 3 
presentavano un adenoma CYP11B1 positivo e alcuni cluster di cellule CYP11B2 positive (2%); 
nel pattern 4 non era presente un adenoma riconoscibile ma cluster di cellule CYP11B2 positive 
(25%); infine, i surreni del pattern 5 non mostravano alcun adenoma ma diversi noduli 
prevalentemente positivi per CYP11B1 e cluster di cellule CYP11B2 positive (11%).   
Al baseline, il pattern 2 si distingueva dagli altri patterns per la maggiore prevalenza di pazienti con 
una mutazione al KCNJ5 (p=.012) e di genere femminile (p=.005).  L’H-score per CYP11B2 negli 
APA era direttamente proporzionale alla concentrazione di aldosterone (r=0.388, p=.002), mentre 
l’H-score per CYP11B1 non era correlato con la concentrazione plasmatica di cortisolo.  Dopo la 
surrenectomia, né la classificazione in patterns né l’H-score sono stati in grado di predirre 
l’outcome biochimico dei pazienti.  Tuttavia, i pazienti che dopo surrenectomia mostravano 
correzione del quadro biochimico ma continuavano ad essere ipertesi erano classificati 
prevalentemente come pattern 3. 
Conclusioni.  Gli anticorpi specifici per CYP11B2 e CYP11B1 permettono di identificare cinque 
patterns immunofenotipici, molto variabili tra loro.  La metodica sviluppata dal nostro gruppo per la 
quantificazione dell’H-score che tiene in considerazione tutte le strutture potenzialmente abili alla 
produzione dell’aldosterone, ovvero APA, clusters e noduli, fornisce informazioni accurate sulla 
produzione di aldosterone nei pazienti con PA. 
In conclusione, i risultati di questo studio mostrano che le forme di PA siano molto più eterogenee 
di quanto precedentemente ipotizzato, suggerendo che accanto all’APA classico definito come 
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nodulo iper-funzionante e all’iperplasia esistano altri fenotipi che includono clusters e/o cellule che 
esprimono entrambi gli enzimi steroidogenici CYP11B2 e CYP11B1.  
L’immuno-staining dei surreni con hCYP11B2 sembra essere un promettente strumento non solo 
per la diagnostica ma anche per lo studio della fisiopatologia dell’iperaldosteronismo.
 8
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INTRODUCTION 
High blood pressure (HBP) is a major cardiovascular risk factor for myocardial infarction, 
congestive heart failure, stroke and end-stage kidney disease.  With nearly 1.56 billion people of the 
world’s adult population estimated to develop HBP in the year 2025,
1
 this risk factor will reach 
epidemic proportions, resulting in a major public health problem and also a huge economic burden. 
An effective anti-hypertensive therapy can highly reduce or even abolish the BP-related risk of 
cardiovascular disease; hence, the reduction of BP is of critical relevance today.
2
  Secondary 
hypertension, a term used for the hypertension for which there is an identifiable cause, accounts for 
at least 40-50% of all hypertensive patients at referral centers.
3,4
  The rate of secondary 
hypertension (HT) was recently reported to be 50% in patients drug-resistant HT.
5
  Although this 
form of hypertension is rare, identification and treatment of the underlying cause might lead to the 
cure or significant improvement of BP.  Thus substantial attention should be made to identify and 
characterize the secondary causes of hypertension.  
Endocrine Hypertension 
Endocrine hypertension ranks amongst the most common causes of secondary hypertension.  The 
most prevalent form is primary aldosteronism, that will be discuss in detail in the next section, 
followed by pheochromocytoma paraganglioma (PPGL), Cushing's syndrome, hypothyroidism, 
hyperparathyroidism, acromegaly, rare forms of mineralocorticoid hypertension (e.g. apparent 
mineralocorticoid excess and Liddle's syndrome). 
PPGL are neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla and 
produce, metabolize and usually, but not always, secrete epinephrine, norepinephrine, dopamine 
and a number of other substances that are responsible for the common symptoms that are associated 
with this disease, e.g. high heart rate, headache, dyspnea, flushing and anxiety.
6,7
  The prevalence of 
PPGL due to the lack of prospective studies, is not known precisely although it has been reported to 
occur in 0.05–0.2% of hypertensive individuals.
8,9
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Cushing's syndrome is a condition characterized by a chronic and inappropriately high exposure of 
tissues to glucocorticoids, which is caused by excessive secretion of ACTH in 80% of cases.
10
  In 
Cushing's syndrome the normal cortisol feedback mechanism of the hypothalamic-pituitary-adrenal 
axis is disturbed, with loss of circadian rhythm and excess cortisol production resulting in 
hypercortisolism.  Incidence of the disorder ranges from 0.7 to 2.4 per million population per year.
11
  
In screening studies of obese patients with type 2 diabetes, especially those with poor blood glucose 
control and hypertension, the reported prevalence of Cushing's syndrome is between 2% and 5%.
12
 
Hyperparathyroidism is a common endocrine disorder characterized by oversecretion of parathyroid 
hormone (PTH), which may be autonomous (independent of serum calcium levels) or the result of a 
physiological stimulus.
13,14
  This disease is generally divided into three types: primary 
(autonomous), secondary (that results from a chronic stimulus causing PTH secretion) and tertiary 
(autonomous PTH oversecretion from secondary parathyroid hyperplasia).
15
  The incidence of this 
disorder is closely related to the frequency of routinely obtained biochemical screening tests, 
socioeconomic issues (i.e. low vitamin D status), dietary habits (i.e. calcium and vitamin D 
supplementation), as well as the degree of awareness among physicians.
16
  Not unexpectedly, these 
varying conditions affect the rate of this disease in different countries.  In Italy, a recent study 
reported that the mean hospitalization rate is 12.9/100000 inhabitants per year.
17
 
Acromegaly is characterized by pituitary somatotroph adenomas that hypersecrete growth hormone 
(GH), which raised the levels of insulin-like growth factor 1.
18
  Common clinical manifestations 
include hypertension, skeletal and soft tissue overgrowth, particularly in the face and extremities, as 
well as headache and arthritis.
19
  The prevalence of acromegaly is estimated to be 8–24/100.000.
20
  
Primary Aldosteronism 
Primary Aldosteronism (PA) is the most common endocrine form of secondary arterial hypertension 
among the patients referred to specialized centers for arterial hypertension
21
 and among patients 
with resistant hypertension.
22
  PA comprises a group of disorders characterized by excess 
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aldosterone production.
23
  Aldosterone secretion is normally stimulated by angiotensin II and 
potassium, whereas in PA, aldosterone production is inappropriately high, relatively independent 
from the renin angiotensin system and/or potassium and is not suppressed with sodium overload.
24
  
Overproduction of aldosterone induces high blood pressure values, sodium retention, increased 
potassium excretion leading to hypokalemia, suppression of plasma renin, and finally 
cardiovascular damage.
25
   
The biochemical picture of PA can be caused by either bilater adrenal hyperplasia (60-65%) or 
unilateral adrenal hyperplasia (2-3%), aldosterone-producing adenoma (APA) (30-35%), 
aldosterone-producing adrenocortical carcinoma (<1%), glucocorticoid-remediable aldosteronism 
(GRA) (familial hyperaldosteronism type I (FH-I)) <1%, familial hyperaldosteronism type II (FH-
II) <1%, familial hyperaldosteronism type III (FH-III) <1% and ectopic aldosterone-producing 
adenoma or carcinoma <1%.
26
 
Familial Forms of PA 
GRA is characterized by the autosomal dominant transmission of severe early onset aldosteronism 
and hypertension.
27
  This disorder is caused by a chimeric gene deriving from a recombination 
between the coding sequences of the aldosterone synthase (CYP11B2) and the promoter sequences 
of 11β-hydroxylase (CYP11B1) genes, both located on chromosome 8.
28
  This leads to synthesis of 
aldosterone no longer regulated by the renin-angiotensin system but, under control of ACTH.
29
   
FH-II is a familial form of unknown genetic basis that has been shown to be in linkage with 
chromosomal region 7p22 in families from different continents.
30
  Cases can present clinically with 
APA or bilateral hyperplasia, and are indistinguishable from patients with sporadic primary 
aldosteronism.
31
   
FH-III was discovered starting from 2011 after the identification of somatic mutations in the 
KCNJ5 gene encoding the GIRK4 K
+
 channel.
32
  Choi et al. described a threonine (Thr)-to-alanine 
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(Ala) substitution at codon 158 in the KCNJ5 gene, resulting in reduced K
+
 selectivity, increased 
Na
+
 conductance and cell membrane depolarization.  After this report, several germ-line KCNJ5 
mutations were independently detected in patients presented with different clinical degrees of PA 
(G151E, I157S, Y152C, E145Q).
33-36
  In 2014, our group also identified one novel mutation in the 
KCNJ5 gene (c.446insAAC) causing PA with severe drug-resistant HT.
37
  Based on the available 
knowledge of this disease, Lenzini and Rossi proposed a new classification for FH-III as a genetic 
disease made of two subtypes, one severe (Type A) presenting severe aldosteronism and bilateral 
massive adrenal hyperplasia requiring bilateral laparoscopic adrenalectomy and one milder (Type 
B) with much less adrenal hyperplasia and drug-responsive HT (Table 1).
38
   
 13
Table 1.  Clinical molecular classification of Familial Hyperaldosteronism 
Type Subtypes Transmission Gene Mutation 
CT 
Finding 
Treatment/ 
Response 
FH-I  Au Dom 
CYP11B2/CYP11
B1 Chimeric 
BAH or 
APA 
Dexamethasone/Correction 
FH-II  Au Dom Gene Unknown 
BAH or 
APA 
MRA or 
Adrenalectomy/Correction 
FH-III 
Type A Au Dom 
KCNJ5 (T158A, 
I157S, E145Q) 
BAH 
MRA/Drug Resistant 
Hypertension 
TypeB Au Dom 
KCNJ5 (G151E, 
Y152C) 
BAH 
MRA/MRA Responsive 
Hypertension 
 
FH: familial hyperaldosteronism; BAH: bilateral adrenal hyperplasia; APA: aldosterone producing 
adenoma; MRA: mineralocorticoid receptor antagonist. 
 
Modified from Lenzini and Rossi, Curr Opin Pharmacol. 2015. 
 
Sporadic Cases of PA 
The two most common causes of sporadic PA are APA and idiopathic hyperaldosteronism with 
bilateral adrenal hyperplasia (BAH), which account for more than 90% of clinical cases.
26
  The 
differential diagnosis between APA and BAH is crucially important for the choice of treatment: 
adrenalectomy can cure or ameliorate hypertension in 55% of patients
39
 whereas patients with BAH 
can be pharmacologically treated with mineralocorticoid receptor antagonists.
21
  Currently, the only 
reliable procedure allowing differentiation of the unilateral from bilateral PA and identification of 
APA side preoperatively is adrenal venous sampling (AVS).
40-42
  In medical centers where AVS is 
available and strict cutoff values for the lateralization index are used,
43
 almost two thirds of PA 
cases are attributed to an APA whereas one third remains by exclusion classified as bilateral 
idiopathic forms.  The opposite is seen when AVS is unavailable, thus explaining the key role of 
AVS for subtyping.
44
  The diagnosis of APA is usually established when the following ‘Four 
Corners Criteria’
44
 are satisfied: 1) there is evidence of PA at the screening tests, with an 
inappropriately high aldosterone-to-renin ratio, 2) aldosterone secretion is lateralized at AVS, 3) an 
adenoma is detected at pathology, and, crucially important, 4) PA is corrected by adrenalectomy.  
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However, at pathology the identification of an APA may be challenging because of the lack of 
clearcut criteria to define the aldosterone-producing cells.
45
   
Pathologists routinely perform hematoxylin and eosin (HE) staining of the adrenal gland to detect 
the presence of one or more nodules that are strongly suggestive of APA, and then identify the cell 
type that is predominant in the nodule(s): compact small cells or large foamy lipid-rich cells.  
However, a mixture of both cell types can be frequently found in the nodule(s), even in association 
with atypical cells characterized by nuclear enlargement, nucleoli and/or hyperchromasia.  The 
histological criteria to distinguish between an adenoma and a nodule are not well defined.  Benign 
or malignant neoplasms are most often monoclonal, but clonality determination is not usually done 
and a clear definition of an adenoma on strict histological characteristics is not forthcoming.
46,47
  
The presence of multiple nodules in an adrenal cortex often is interpreted as being multiple 
adenomas or nodular hyperplasia depending on the observer.
48
  Most APAs also exhibit zona 
glomerulosa hyperplasia,
49
 but this is open to histological interpretations and, moreover, according 
to some groups this is seldom seen.
36
  Nevertheless, since HE staining provides no information on 
the functional phenotype, whether the nodule(s) is responsible for the over-production of 
aldosterone remains uncertain.  In the attempt of overcoming such hindrance, an approach based on 
specific oligonucleotides for the CYP11B2 for the in situ hybridization (ISH) technique was used in 
some laboratories to ascertain the ability of the nodules found in adrenal specimens from PA 
patients of synthesizing aldosterone.
50,51
  However, being time-consuming and difficult in its 
implementation, ISH is not feasible for every-day hospital histopathology.  
An approach based on immunohistochemistry (IHC) would be strongly desirable as it is faster and 
less expensive than ISH, suitable for automated systems and, therefore, can be routinely used by 
most diagnostic pathology services.  After a long quest over decades, finally antibodies against 
human CYP11B2 and 11β-hydroxylase (CYP11B1) have been successfully developed.
52,53
  
Currently their use is restricted to few research laboratories and not yet commercially attainable, 
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IHC has remained an impracticable approach for the routine diagnostic work-up of the APA.  
Commercial antibodies are available from several companies, unfortunately more often than not the 
immunizing peptide is proprietary and the validation uncertain as some of them are described in the 
catalogues showing strong staining or western blots in tissues or cell lines that do not express the 
enzyme.  Nonetheless, the development of these antibodies should not only allow unequivocal 
detection of aldosterone- and cortisol-producing cells, but also may shed new light on the histology 
of normal adrenal gland and APA.  In fact, use of the specific antibodies against CYP11B2 and 
CYP11B1 unexpectedly unveiled that different patterns of CYP11B1 and CYP11B2 can be 
associated with what was clinically diagnosed as an APA, thereby questioning the 'classic' view of 
APA as a single, well demarcated or encapsulated nodule exclusively constituted by cells producing 
excess aldosterone.  
Expression and Detection of CYP11B2 and CYP11B1 in the Adrenal Cortex  
In the normal adrenal gland aldosterone production occurs in the outer part of the adrenal cortex, 
the Zona Glomerulosa (ZG), and it is regulated primarily by Na
+
 intake via the RAS, by plasma K
+
 
concentration, and by ACTH levels.
54
  ZG cells are hyperpolarized by K
+ 
influx through different 
channels.  When a stimulus takes place, the cell membrane depolarizes and this results in enhanced 
Ca
2+
 intake via L-, N- and T- type Ca
2+
 channels.
55,56
  Moreover, mobilization of intracellular Ca
2+ 
from the endoplasmic reticulum further increases intracellular Ca
2+
 load,
54
 with phosphorylation of 
transcription factors and activation of CYP11B2 gene transcription.  CYP11B2 encodes for the 
enzyme aldosterone synthase, a multifunctional cytochrome enzyme, which first hydroxylates 
deoxycorticosterone (DOC) at the 11β-position to form corticosterone, then at the 18-position to 
generate 18-hydroxycorticosterone.  The bound 18-hydroxycorticosterone is then finally 
hydroxylated at the 18-position to generate a germinal diol that spontaneously and rapidly 
dehydrates to form aldosterone.  The aldehyde at C18 of aldosterone exists in equilibrium with its 
hemiacetal form (Figure 1). 
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Figure 1.  Aldosterone synthesis 
Modified from Roumen L, Sanders MP, Pieterse K et al. J Comput Aided Mol Des. 2007  
 
In the cortisol-producing Zona Fasciculata (ZF) cells the enzyme 11β-hydroxylase, which is coded 
by CYP11B1 gene, converts 11-deoxycortisol and DOC to generate cortisol and corticosterone.  
Both CYP11B2 and CYP11B1 are mitochondrial enzymes that share 93% amino acid sequence, 
making it difficult to generate specific antibodies able to reliably distinguish between the 
enzymes.
57,58
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Synthesis of Monoclonal Antibodies against CYP11B2 and CYP11B1 
Two decades ago, Ogishima et al
52
 generated polyclonal antibodies for CYP11B2 and CYP11B1 by 
synthesizing oligopeptides (figure 2) corresponding to the 80-90 amino acid residues
57
 and coupling 
them to equine myoglobin to immunize domestic rabbits, but only recently reported their use.
59
  
More recently, monoclonal antibodies against the two human steroidogenic enzymes have been 
developed in Gomez-Sanchez’s laboratory, with whom we collaborate.
53
  Five different 
immunization peptides were designed to cover the area where CYP11B2 and CYP11B1 amino 
acids sequences diverge.  After injecting Swiss-Webster mice for CYP11B2 and Sprague-Dawley 
rats for CYP11B1 with the conjugated peptides, the spleen cells from the animals with the highest 
titers and lowest cross-reactivity were fused to modified mouse myeloma SP2-mIL6-hIL21 cells in 
order to obtain monoclonal antibodies.  The antibody against CYP11B2 was obtained from the 
animals injected with the 41-52 amino acid sequence shown in figure 2 (highlighted in green).  This 
sequence differs from that previously used by Ogishima et al.
52
  The antibody against CYP11B1 
was achieved from rats inoculated with a peptide corresponding to the 80-90 aa sequence and that 
used by Ogishima in 1991.  ELISA and western blot analysis confirmed the speciﬁcity of the two 
antibodies against CYP11B2 and CYP11B1.
53
  Monoclonal antibodies produced from hybridoma 
cells are of an antibody type against a limited epitope, thus have a clear advantage over polyclonal 
antibodies that may change from bleeding to bleeding and animal to animal.  In addition, their 
quantities are theoretically unlimited as long as the hybridoma cell line is preserved.  Therefore, 
these novel monoclonal antibodies seem to be the most promising tools to investigate the adrenal 
disorders. 
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B1  MALRAKAEVC MAVPWLSLQR AQALGTRAAR VPRTVLPFEA MPRRPGNRWL 
B2  MALRAKAEVC VAAPWLSLQR ARALGTRAAR APRTVLPFEA MPQHPGNRWL 
    51                                                 100 
B1  RLLQIWREQG YEDLHLEVHQ TFQELGPIFR YDLGGAGMVC VMLPEDVEKL 
B2  RLLQIWREQG YEHLHLEMHQ TFQELGPIFR YNLGGPRMVC VMLPEDVEKL 
    101                                                150 
B1  QQVDSLHPHR MSLEPWVAYR QHRGHKCGVF LLNGPEWRFN RLRLNPEVLS 
B2  QQVDSLHPCR MILEPWVAYR QHRGHKCGVF LLNGPEWRFN RLRLNPDVLS 
    151                                                200 
B1  PNAVQRFLPM VDAVARDFSQ ALKKKVLQNA RGSLTLDVQP SIFHYTIEAS 
B2  PKAVQRFLPM VDAVARDFSQ ALKKKVLQNA RGSLTLDVQP SIFHYTIEAS 
    201                                                250 
B1  NLALFGERLG LVGHSPSSAS LNFLHALEVM FKSTVQLMFM PRSLSRWTSP 
B2  NLALFGERLG LVGHSPSSAS LNFLHALEVM FKSTVQLMFM PRSLSRWIRP 
    251                                    C           300 
B1  KVWKEHFEAW DCIFQYGDNC IQKIYQELAF SRPQQYTSIV AELLLNAELS 
B2  KVWKEHFEAW DCIFQYGDNC IQKIYQELAF NRPQHYTGIV AELLLKAELS 
    301                                                350 
B1  PDAIKANSME LTAGSVDTTV FPLLMTLFEL ARNPNVQQAL RQESLAAAAS 
B2  LEAIKANSME LTAGSVDTTA FPLLMTLFEL ARNPDVQQIL RQESLAAAAS 
    351                                                400 
B1  ISEHPQKATT ELPLLRAALK ETLRLYPVGL FLERVASSDL VLQNYHIPAG 
B2  ISEHPQKATT ELPLLRAALK ETLRLYPVGL FLERVVSSDL VLQNYHIPAG 
    401                                                450 
B1  TLVRVFLYSL GRNPALFPRP ERYNPQRWLD IRGSGRNFYH VPFGFGMRQC 
B2  TLVQVFLYSL GRNAALFPRP ERYNPQRWLD IRGSGRNFHH VPFGFGMRQC 
    451                             C                  500 
B1  LGRRLAEAEM LLLLHHVLKH LQVETLTQED IKMVYSFILR PSMFPLLTFR 
B2  LGRRLAEAEM LLLLHHVLKH FLVETLTQED IKMVYSFILR PGTSPLLTFR 
    501          C 
B1  AIN 
B2  AIN 
 
Figure 2.  Comparative alignment of the protein sequence between human CYP11B1 and CYP11B2 
The red letters indicate the amino acid differences between the sequences. The green highlighted 
letters are the sequences used by Gomez-Sanchez for synthesis of CYP11B2 peptides. Highlighted 
in yellow letters are the sequences used by Ogishima and Gomez-Sanchez for synthesis of 
CYP11B1 peptides, those highlighted in blue are the sequences used by Ogishima for synthesis of 
CYP11B2 peptides. 
 
Histology of the Normal Human Adrenal Gland 
In the classical view three major zones compose the adrenal cortex: the outermost ZG, the midzone 
ZF and the innermost Zona Reticularis (ZR), with ZG and ZF cells producing aldosterone and 
cortisol, respectively.
60
  The functional zonation in humans was originally presumed based on 
histology and biochemistry of rodent adrenals,
61-63
 with no direct evidence from humans.  Only 
recently, immunostaining of the normal human adrenals with Ogishima’s antibodies showed where 
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cells expressing the enzymes are actually distributed in the human adrenal cortex under normal and 
pathological conditions.  In 2010 Nishimoto et al. revealed two types of CYP11B distribution, 
termed 'conventional' and 'variegated’.
59
  Conventional distribution shows a zonation similar to that 
described in rodents: three different zones (ZG, ZF, and ZR) where CYP11B2 can be sporadically 
detected in the cells of the upper portion of the ZG cords underneath the capsule, whereas 
CYP11B1 is found in both ZF and ZR.  In the variegated pattern there are clusters of cells strongly 
positive for CYP11B2 in the sub-capsular area, with the rest of the cortical area expressing 
CYP11B1.  The clusters, also called aldosterone-producing cell clusters (APCCs),
59
 are usually 
characterized by a width of 200-1300 μm and a depth of 100-500 μm beneath the capsule; 
occasionally, they are in direct contact with the capsule.  APCCs also express 3β-hydroxysteroid 
dehydrogenase (3βHSD), but not 17β-hydroxylase/17,20-lyase (CYP17), the enzyme required for 
the synthesis of the cortisol precursor 17α-hydroxypregnenolone, and are surrounded by columnar 
ZF-like cells forming cords along sinusoids.  The cells in sub-capsular areas that are devoid of 
APCCs lack both CYP11B1 or CYP11B2. 
The most recent monoclonal antibodies developed in the Gomez-Sanchez’s laboratory confirmed 
the existence of variable patterns of the human adrenal cortex.  The analysis of normal adrenals 
from 4 adults and one 5 days old infant documented that CYP11B2 immuno-reactive cells exhibited 
the two patterns: the first characterized by scattered cells, and the other identified by more tightly 
clustered cells, i.e. APCC.  CYP11B1 positive cells extended up to the capsule in many portions of 
the cortex and were intermingled with CYP11B2 immuno-positive cells.
53
  Double staining 
demonstrated that CYP11B2 and CYP11B1 were mostly expressed in different cells, but double 
immuno-reactive cells were occasionally found in the sub-capsular region.  
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Adrenocortical Steroidogenic Zonation with Aging 
The adrenal cortex samples from adults had relatively few CYP11B2 immuno-reactive cells close to 
the capsule when compared to the infant adrenal, which showed many more.
53,59,61-63
  The higher 
plasma levels of aldosterone in infants, compared to normal adults, is presumably due to the low 
expression of the mineralocorticoid receptor and the partial resistance to aldosterone.  Therefore a 
relationship between cell type distribution and adrenal function was contended.
53,59,61,62,64,65
   
This contention is also consistent with the findings obtained from an analysis of 61 surgically- or 
autopsy-derived adrenals removed from patients ranging from 1 day to 92 years old with no obvious 
hormone abnormalities.  The adult adrenals were found to have less CYP11B2 immuno-reactive 
cells than those in the infants, suggesting that adrenal zonation changes with aging alongside basal 
aldosterone levels.
64
 It may also reflect the relatively high sodium levels in diet. Homogeneous 
columns of ZF cells topped with ZG cells mainly constituted the sub-capsular cortex from birth to 
adolescence, occupying more than half of the adrenal circumference.  Starting from adolescence, 
cells that do not express either CYP11B1 or CYP11B2, but express 3βHSD and P450scc, also 
known as zona progenitor (ZP) cells, appeared and gradually occupied the upper portion of the 
cortical cords.
64
  After the 40s, ZP cells became the prevailing cell type in the uppermost zone of 
the cortex, leaving ZG cells organized in scattered clusters.  Of importance, the 
immunohistochemically defined ZG, ZF and ZP cells did not correspond to the HE staining-defined 
ZG-like or ZF-like cells,
64
 thereby suggesting that functional zonation does not correspond to the 
morphologic zonation and that HE analysis is unable to identify aldosterone-producing clustered 
cells or an APA.  
The functional role of ZP cells is unknown.  Many studies have provided evidence for the existence 
of adrenocortical cells with stem-like capacities across mammalian species and undifferentiated 
adrenocortical cells with limited or no steroidogenic activity, i.e. ZP cells, thereby suggesting a role 
in adrenal gland development and functional plasticity.
66-69
  According to another hypothesis ZP 
cells are steroidogenic latent cells that could differentiate in either ZG or ZF according to further 
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stimulation.
70
  More ZG cells seem to be needed at birth and during adolescence than in senescence, 
probably because plasma volume expansion is a prerequisite for growth.  Accordingly, after the 
reproductive age and a consistently sodium repleted diet, ZG-cell stimulation would decrease and 
they would lose their ability to synthesize hormones, thereby becoming ZP cells.  Similarly, 
decreased need for gluconeogenesis and HPA activity would decrease the requirement for cortisol 
synthesis, thus ZF cells would also be transformed to ZP cells.  Such a theory, which explains the 
onset of ZP cells along with ZG/ZF cell involution, is consistent with the higher aldosterone levels 
measured in the newborns and children than in the adults.
65,71-73
  Whether the number of ZG cells, 
and consequently of ZP cells change, i.e. in response to sodium intake, remains unclear, although 
evidence from experimental models supports this contention.
70-72,74
  Cells that express neither 
CYP11B1 nor CYP11B2 were found to be more abundant in the adrenals obtained from rats 
maintained under low stress conditions on a standard or high sodium diet and mingling with cells 
expressing the CYP11B2 enzyme,
75
 and the width of the zona glomerulosa and the number of 
CYP11B2 positive cells markedly increased in chronically sodium-depleted rats.  However, adrenal 
analysis after manipulation of sodium intake is only possible in experimental animals, but not in 
humans for obvious reasons.  Thus, the role of ZP cells in human adrenals can only be inferred.  
Moreover, human adrenals are usually obtained from autopsy, often from patients who died after 
illness that involved stress and/or electrolyte derangements.  Adrenal morphology and function 
under these circumstances by no means reflect normal physiological status.
53
 
Adrenal Tissue Adjacent to the APA 
The adrenal tissue adjacent to an APA may show either a pattern similar to that observed in the 
normal adrenal, consisting of diffuse CYP11B1 immuno-reactivity in ZF and ZR
53
 and sporadic 
expression of CYP11B2 in ZG,
59
 or a pattern resembling the APA, with APCCs expressing 
CYP11B2 and 3βHSD but not CYP11B1 or CYP17.  The peri-tumoral tissue often shows micro- 
and/or macro-nodules, with some expressing CYP11B2,
49,59,76
 thereby suggesting active aldosterone 
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production in the area surrounding APAs.  These findings were consistent with those found with the 
ISH analysis, which showed mRNAs of steroidogenic enzymes necessary for aldosterone 
production (CYP11B1, CYP11B2, HSD3B2, CYP21A2) in sub-capsular micronodules adjacent to 
APAs.
77
  Collectively, these findings suggest that, in contrast with current opinion, a clear boundary 
between APA and adjacent tissue does not exist; moreover, co-existing sub-capsular micronodules 
might be the initial foci for the development of APA. 
Histology of the APA 
The diagnosis of APA includes demonstration of an adenoma, classically depicted as a single and 
round macronodule in the adrenal gland, consisting of morphologically ZG- or ZF-like cells, or a 
combination of both.
78
  HE staining  currently used to reveal the APA and discriminate between 
ZG- and ZF-like cells cannot provide any information on the function and steroidogenic potential of 
these cells (figure 3, panel A).  Using the Ogishima’s antibodies, Nishimoto et al. identified three 
cell types within the APA (figure 3, panel B): 1) cells positive for CYP11B2 but negative for 
CYP11B1, 2) cells positive for CYP11B1 but negative for CYP11B2, and 3) cells negative for 
either CYP11B1 or CYP11B2.
59
  No cells showing double staining for CYP11B1 and CYP11B2 
were found.
59
  In contrast, Nakamura et al. reported that APAs contained not only a mix of 
CYP11B2 and CYP11B1 positive cells, but also cells expressing both CYP11B enzymes.
79
  
Immunoreactivity for CYP11B1 tended to be diffuse within the APA, whereas that for CYP11B2 
was quite heterogeneous and spotted.
79
  CYP11B1 was strongly expressed outside the adenoma, 
while there was little expression of the CYP11B2 outside the adenoma.  CYP11B1, but not 
CYP11B2, co-localized with CYP17 in most APA cells.
79
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Figure 3.  Identification of an APA using either hematoxylin and eosin (HE) (panel A on 
the left) or antibodies against CYP11B1 and CYP11B2 (panel B on the right). 
 
Panel A. HE allows identification of zona glomerulosa like cells (visualised as pink cells), zona 
fasciculata like cells (yellow cells) and zona reticularis like cells (light pink cells). The cell 
phentoypes are shown in different colours (arbitrary chosen) to enable their distinction. Using 
HE staining ZG-cells appear as small and markedly stained with eosin because of the presence of 
mitochondria whereas, ZF-cells appear as large and light cells due to the great abundance of lipid 
drops. The appearance of ZR-cells is quite similar to that of ZG-cells as small pink cells. 
However, HE does not provide functional information about steroidogenesic capacity. Note that 
the human adrenal ZG does not form a continuous layer under the capsule as in rodents; the ZG-
cells aggregate in clusters. APA cells mostly appear as ZF-cells, with only a few intermingled 
ZG-cells.  
Panel B. IHC using CYP11B1 and CYP11B2 allows identification of cortisol- and aldosterone-
producing cells as green cells and brown cells, respectively, this showing that IHC provides 
functional information on steroid production. The sub-capsular clusters usually show 
immunoreaction against CYP11B2, whereas cells forming cords exibit immunoreaction against 
CYP11B1. Both CYP11B1 and CYP11B2 positive cells can be detected in the APA suggesting 
that there is no perfect matching between ZF-cells, which are commonly detected within the 
APA with HE, and cells producing aldosterone, i.e. CYP11B2 positive cells. Since neither 
aldosterone nor cortisol are produced by ZR-cells no specific immunoreactive signal can be 
detected. 
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Since the intensity of the immunostaining differed markedly across APAs, some investigators 
hypothesized that this could reflect the magnitude of the steroidogenesis in the tumor and that a 
relationship exists between CYP11B2 or CYP11B1 expression, aldosterone production, and the 
tumor size.  Using a very simple semi-quantitative system that assigned a score 1 to dimly 
immuno-stained APAs and 2 or 3 to well, or very markedly, respectively, stained tumors, Nanba 
et al. found that the score for CYP11B2 inversely correlated with the tumor size calculated by 
assuming a spherical shape of the tumor
76
.
76
  When adjusting the CYP11B2 score for the tumor 
volume, Nanba found a positive correlation between CYP11B2 staining score and plasma 
aldosterone concentration (PAC) or the aldosterone-to-renin ratio (ARR).  The score negatively 
correlated with serum K
+ 
levels, thus leading support to the hypothesis that CYP11B2 score 
reflects aldosterone synthesis.
76
  By exploiting a more complex scoring system, in which the 
percentage of the stained cells in the APA is multiplied by a factor ranging from 0 to 3 to reflect 
the intensity of cell immunostaining,
80
 Nakamura et al. observed that CYP11B2 H-score in the 
APA (44.0+5.1, mean+SE) was not significantly different from that calculated in the normal 
adrenal gland (58.6+9.5, mean+SE), but was higher than that measured in the tissue adjacent to 
the APA (24.5+4.9, mean+SE).
79
  In contrast to Nanba,
76
 they found no relationship between 
intensity of CYP11B1 or CYP11B2 immunostaining and tumor size or age,
79
 leaving unclear 
whether the intensity of immunostaining truly reflects the amount of steroidogenesis.  However, 
experimental evidence with cultured cells and animals suggests that it would. 
Because of the not perfectly circular shape of the tumors, Ono et al. determined the precise area of 
the lesion using the specific software ImageJ.
81
  They found that the values differed significantly 
from the circular area calculated on the basis of the maximum diameter.
81
  By analysing a series of 
40 APAs they reported that the CYP11B2 H-score was higher in APAs with an area smaller than 
the median value of 60mm
2
, compared to those with an area ≥60mm
2
, suggesting that small APAs 
produce more aldosterone per cell than large tumors consistently with what reported by Nanba et 
al.
76
  However, when CYP11B2 H-score was multiplied by tumor area, the resulting value 
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correlated positively with PAC.
81
  Using different CYP11B1 & CYP11B2 antibodies Monticone et. 
al. also observed an inverse correlation between intensity of CYP11B2 expression and nodule size, 
and a positive correlation of CYP11B2 expression corrected for tumor volume with PAC and 
ARR.
82
  They also found that patients not expressing CYP11B1 had lower serum potassium levels 
compared to patients expressing CYP11B1 in the adrenal nodule, but neither absolute aldosterone 
nor ARR levels differed between groups.
82
   
Somatic Mutations in the Potassium Channel Kir3.4 
The recent discovery of somatic mutations in the KCNJ5 gene opened a new window on the 
molecular mechanisms that control the autonomous aldosterone synthesis in APA.  KCNJ5 encodes 
for the potassium channel Kir 3.4, which allows the selective transport of K
+
 through the cell 
membrane to the extracellular space, keeping the membrane hyperpolarized.
83
  Choi et al.
32
 first 
reported that G151R and L168R mutations causing the insertion of a positive charged amino acid 
into the selectivity filter of the channel resulted in loss of selectivity for K
+
, with ensuing leak of 
Na
+
 into the cell, membrane depolarization, increased [Ca
2+
]i, and finally CYP11B2 gene activation 
(Figure 4).  
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Figure 4.  Proposed mechanism underlying aldosterone-producing adenoma and KCNJ5 
mutation. 
Modified from Choi et al. Science 2011. 
 
 KCNJ5 mutated APAs consisted mainly of ZF-like cells with high expression of CYP11B1.
78,82
  
CYP11B2 immunostaining allowed identification of one case of two CYP11B2 positive nodules in 
the same APA exhibiting the same KCNJ5 mutation, and one case reporting two nodules carrying 
two different KCNJ5 mutations (L168A and G151A).
78
  Sequencing of APAs with no KCNJ5 
mutations led to the discovery of somatic mutation of the sodium/potassium ATPase gene ATP1A1, 
the calcium ATPase gene ATP2B3 and the voltage-gated Ca
2+
 channel Cav 1.3 gene 
CACNA1D.
84,85
  The loss-of-function mutations in ATPs and Ca
2+ 
channels resulted in increased 
intracellular [Ca
2+
] load that activates aldosterone secretion via the calcium-calmodulin pathway.  
ATP1A1 and CACNA1D mutations were found in multinodular glands, whereas ATP2B3 mutation 
only in solitary adenomas.
78
  APAs with the ATP1A1, ATP2B3 and CACNA1D mutation most 
frequently had a ZG-like phenotype with high expression of CYP11B2.
82
  Nodules carrying an 
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ATP2B3 mutation were smaller than those containing a KCNJ5 mutation and, in contrast to KCNJ5 
mutated nodules, did not contain atypical cells.
78
  
Clinical Implications of the Antibodies against CYP11B1 and CYP11B2 
Since these selective antibodies were made widely available a few years ago several different 
studies were performed to analyze the CYP11B2/CYP11B1 immuno-histochemical expression and 
clinical outcome of APA patients.
78,86,87
  By analyzing 53 adrenals removed at surgery due to 
unilateral PA, Dekker et al. observed that at follow-up the patients with a solitary adenomas were 
cured more often than those with nodular hyperplasia.
78
  Volpe et al. retrospectively studied 120 
consecutively unilaterally adrenalectomized patients selected on the basis of the AVS or NP59
 
scintigraphy.  In six of their cases (7%), the initial diagnosis was changed from APA to aldosterone-
producing hyperplasia after immunohistochemistry investigation; moreover, in 5 of these 6 
specimens, the “adenoma” was CYP11B1, not CYP11B2 positive.
87
  To date studies searching for a 
relationship between IHC pattern and clinical outcome have limitations in that they were 
retrospective, often spanning a long period of time, without uniform diagnostic work-ups for PA.  
The diagnostic strategies included CT scan, or AVS, or both, but it is well established that CT can 
be misleading in identifying the side causing lateralized excess aldosterone production in up to 50% 
of the cases.
88
  Therefore it could be that, in some cases, the removed adrenal lacked of nodules 
with CYP11B2 positive cells simply because of side misclassification.  
Due to these limitations, the clinical implications of the different cell type patterns, in terms of 
prediction of treatment outcome remains to be determined.  Obviously, an optimal approach to 
tackle this question would be by using not just imaging (CT or MR) but also AVS. 
After adrenalectomy hypertension is cured in around 50% of patients with APA (range 33–70%) 
89
 
but the remaining patients continue to require antihypertensive drugs to keep their blood pressure in 
the normal range. Citton et al. failed to identify any evident relationship between the recurrence of 
PA and classical HE histopathology, also at long-term follow-up.
90
  Use of CYP11B2 and 
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CYP11B1 antibodies markedly enhance the accuracy of the APA diagnosis
86,87
 but still leaves 
unclear whether the steroidogenic phenotype of the APAs and the intensity of immunostaining 
could give a clue about the clinical outcome of the adrenalectomized patients.  
 29
GENERAL AIM 
Taking advantage of a novel method to immunohistochemically detect CYP11B1 and CYP11B2, 
this study was aimed at identifying the CYP11B2/CYP11B1 immuno-phenotypes in the adrenal 
glands from PA patients undergoing adrenalectomy at 3 referral centers in Italy.  Moreover, an 
ancillary goal was to investigate whether immunostaining predicts the biochemical profile and/or 
the outcome of APA patients. 
SPECIFIC AIMS 
After identification of the CYP11B2 and CYP11B1 steroidogenic patterns that best describe the 
excised adrenal glands from PA patients, the study was specifically aimed at investigating if a 
specific immuno-phenotype could reflect the clinical profile of PA patients. 
In PA patients before adrenalectomy we investigated if 
1) aldosterone production differs among patterns; 
2) cortisol production differs among patterns; 
3) the staining intensity of CYP11B2 in the adrenal gland correlates with the serum aldosterone 
production; 
4) the staining intensity of CYP11B1 in the adrenal gland correlates with the serum cortisol 
production. 
After adrenalectomy, focusing our attention on the biochemical and clinical profile of PA patients 
we investigated if 
1) the steroidogenic CYP11B2/CYP11B1 patterns differ in BP and aldosterone production 
outcome; 
2) the staining intensity of CYP11B2 and CYP11B1 reflect different aldosterone and cortisol 
production in PA patients. 
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MATERIAL AND METHODS 
Patients 
One hundred and eleven adrenal glands removed from PA patients among those referred to the 
Specialized Centers for Hypertension of the University of Padua (n=64), Rome (n=39) and Pisa 
(n=8) and 16 normal adrenal glands (NAG) from patients who underwent adrenalectomy for renal 
carcinoma were processed for IHC.  56 APAs from the 111 adrenal glands removed for PA were 
genotyped for the most common KCNJ5 mutations.  The patients were submitted to adrenalectomy 
after identification of lateralized excess of aldosterone production according to the current 
guidelines recommendations.
23
  All resected patients had hypertension resistant (defined as blood 
pressure not controlled by two or more drugs, one of which is diuretic), elevated plasma aldosterone 
concentration (PAC) and Aldosterone to Renin Ratio (ARR).   
The diagnosis was based on the ‘four corners’ criteria (specified in Table 2)
44
 and implementation 
of lifestyles measures according to the ESH 2013 guidelines.
91
  
Tissues were obtained under sterile conditions at surgery, in the operating room the excised adrenal 
gland was cut into halves according to the size of the APA. Half of the adrenal was sent to the 
Pathology department for histological study and the remaining tissue was rapidly frozen in liquid 
nitrogen vapor state for further molecular studies.   
An informed written consent was obtained from each patient.   
Table 2.  Four “corners” criteria 
FOUR CORNERS CRITERIA 
Baseline Biochemical diagnosis of PA 
Lateralization of aldosterone secretion at 
bilaterally selective AVS or NP59 scintigraphy 
Follow-UP 
Evidence of adrenocortical nodule 
at histopathology 
Cure or improvement of HT, and correction of 
biochemical picture of PA 
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APA – DNA Preparation 
Genomic DNA was prepared from 56 subject venous blood and tumor tissue by standard procedures 
(Eurogold DNA Extraction kit, Euroclone, Milan, Italy).  Exon 2 KCNJ5 gene was amplified  using 
appropriate primers. PCR was performed on 250ng DNA in a final volume of 50 ul containing 300 
nM MgCl2, 400 nM of each primer, 200 µM deoxynucleotide triphosphate, and 2.6U expand high-
fidelity enzyme mix (Roche Applied Science, Italy).  Purified PCR products underwent direct 
Sanger sequencing using the ABI Prism Big Dye Terminator version 3.1 cycle sequencing kit 
(Applied Biosystems, Foster City, CA) on an ABI Prism 3700 DNA analyzer (Applied 
Biosystems).  In the patients with mutated APA concomitance of germline kir3.4 mutations was 
sought for by sequencing DNA from peripheral blood leucocytes or adrenal tissue surrounding the 
APA.  
APA – cDNA Preparation and Genotyping 
Mutated APA sample’s total RNA was prepared from liquid nitrogen preserved APA tissue using 
RNAeasy Kit (QIAGEN, Milan, Italy) according to the manufacturer’s instructions.  DNA-free 
RNA was prepared using DNAsel (Ambion, Life Technology, CA).  Reverse transcription of 1ug 
RNA was performed with random examer primers using the Iscript cDNA Synthesis kit (BioRad 
Laboratories, Milan, Italy) according to the manufacturer’s instructions. KCNJ5 cDNA was 
amplified using intron-spanning primers and sequenced. 
High Resolution Melting (HRM) Analysis 
Genomic DNA from APA corresponding peripheral blood leukocytes was amplified using SsoFast 
EvaGreen supermix (BioRad) and primers.  Short amplicon covering mutation region of the KCNJ5 
gene was amplified using the CFX96 real-time PCR detection system (BioRad), and results were 
analyzed using the CFX Manager
TM 
and Precision Melt Analysis
TM 
software.  The PCR reaction 
was performed in a 20ul final reaction volume containing 200nmol of each primer and SsoFast
 TM 
EVA Green 5X SuperMix (BioRad).  The system amplification protocol was 95°C for 3 min; 50 
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cycles of 95°C for 10s, 60°C for 30s.  Subsequently, a melt curve was generated by heating from 
65°C to 95°C with 0.2°C increment. Precision Melt Analysis software was then used to identify 
areas of stable pre- and post-melt fluorescence from the HRM curve and automatically determined a 
cluster of each genotype.  Some positive (SNP) and negative (wild type) controls were examined in 
the same PCR and melt reaction to verify the precision of melt analysis.  For each cluster, one 
sample underwent Sanger sequence in order to confirm the false positive sample. 
Immunohistochemistry 
IHC was performed using CYP11B2 and CYP11B1 antibodies
53
 thanks to the collaboration with 
Prof. Celso Gomez-Sanchez at University of Mississippi Medical Center (Jackson, MS, USA), 
where the candidate spent six months during the PhD course.  Paraffin-embedded adrenal was cut at 
5 μm and the sections dried and then melted at 56°C for at least 3 hours.  After deparaffination 
through alcohols, slides were subjected to antigen retrieval using Trilogy (Cell Marque Corp) in 
autoclave, 15 minutes at 121°C, and then treated with phenylhydrazine 0.1% for 20 minutes to 
inhibit endogenous peroxidases.  Slides were blocked with Tris 0.1 M, goat serum 5%, or horse 
serum 5%, SDS 0.5% (pH 7.4) for 1 hour, and then incubated with CYP11B2 antibody 
(hCYP11B2-41-17B clone 1:500 dilution) or both CYP11B1 (CYP11B1-80-7-5 clone 1:200 
dilution) and CYP11B2 (hCYP11B2-41-17B clone 1:500 dilution) overnight at 4°C.  After 
washing, slides were incubated with secondary antibodies for 1 hour at room temperature.  We used 
mouse Polink-2 Plus HRP (GBI Labs) for CYP11B2 immunostaining; rat Polink-2 Plus AP (GBI 
Labs), and ImmPRESS antimouse Ig reagent (Vector Laboratories) for double immunostaining.  
Slides were developed using diaminobenzidine and HighDef green immunohistochemistry 
chromogen AP (Enzo Life Sciences).  All samples were counterstained with Meyer hematoxylin 
(Vector Laboratories) before mounting. 
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Immunofluorescence 
Triple immunofluorescence was done using CYP11B1, CYP11B2, and 17α-hydroxylase
92
 
antibodies.  The protocol followed the procedure used for double immunohistochemistry.  Primary 
antibodies incubation was done with a mixture of rat CYP11B1-80-7-5 clone 1/200, mouse 
CYP11B2-41-17B clone 1/500 and rabbit anti 17α-hydroxylase 1/300 overnight at 4°C.  After 
washing, a combination of highly absorbed antibodies was used, goat anti-mouse IgG Alexa Fluor 
488, goat anti-rat IgG Alexa Fluor 594 and goat anti-rabbit IgG Alexa Fluor 647 (Jackson 
Immunoresearch Inc. Allentown, PA) 1/1000 dilution for 1h at room temperature.  The slides were 
washed and mounted with Vectashield HardSet Mounting Medium with DAPI (Vector Labs, 
Burlingame, CA).  Images were captured using an Eclipse Nikon Microscope with a Rover camera 
and pseudocolored. 
Identification of Patterns Based on IHC using CYP11B2/CYP11B1 Antibodies  
The patterns that characterize the normal and overproducing aldosterone adrenal glands were 
identified using the double IHC with CYP11B2 and CYP11B1 antibodies.
53
  Classification of the 
specimens into so-identified patterns was done independently and blindly by 5 different observers 
(inter-observer agreement k>0.85).  When there was discordance or differences in their evaluation, 
the slides were re-evaluated until a consensus was reached. 
Morphometric analysis of CYP11B2 and CYP11B1 expression  
Immunoreactivity of CYP11B2 and CYP11B1 staining was assessed semi-quantitatively according 
to a modified version of the McCarty H score.
80
  The procedures were performed by using the 
ImageJ software,
93
 freely available at http://rsb.info.nih.gov/ij/, powered by a routine specifically 
developed in our laboratory.  The routine can be summarized as follows. 
1. Image acquisition and pre-processing.  From each section all fields corresponding to the APA, 
nodules or CYP11B2 positive clusters were selected at a primary magnification of 5X and then their 
bright-field images were acquired in full colors (RGB, 24-bit), processed to correct shading and 
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finally filed as TIFF.  Images were acquired by using a Qwin digital camera (Leica, Wetzlar, 
Germany). 
2. Morphometric assessment of the immunoreactive components.  Color thresholding was applied 
to the images to identify the immunoreactive structures in the stained sections.
94
  Pixel colors were 
represented as hue, saturation, and brightness (HSB) values.  Specifically brown-stained structures 
corresponding to the CYP11B2 positive were identified by selecting the pixels with ‘hue’ in the 
red-yellow range and ‘brightness’ lower than the mean brightness level exhibited by the background 
minus two standard deviations (thus excluding the unspecific staining).  To identify the green-
stained components (CYP11B1 positive) the same approach was applied with thresholds for ‘hue’ 
in the green-blue range.  After interactive editing to remove remaining artifacts as dots or breaks in 
the slide, the area fraction occupied by each marker in the tissue and the mean brightness value 
were measured.  The product of these two parameters, i.e. area fraction and brightness; was used as 
the corresponding H-score for CYP11B2 and CYP11B1. 
For each adrenals, we quantified the CYP11B2 and CYP11B1 staining intensity in all the potential 
aldosterone producing structures, including APA, CYP11B2 positive cell clusters and nodules.  In 
addition, we calculated the sum of the CYP11B2 scores or the sum of the CYP11B1 scores of all 
those structures and defined this score as the total CYP11B2 H-score and the total CYP11B1 H-
score, respectively. 
Immunoreactivity of CYP11B2 and CYP11B1 staining was assessed by two different researchers 
with an inter-observer agreement: r> 0.97. 
Statistical Analysis  
All data are presented as mean  ±  SE.  Data were analyzed with SPSS version 23 (IBM, SPSS 
statistics, Bologna, Italy).  After determination of a normal distribution, differences between groups 
were analyzed with Student’s t test for independent samples or one-way ANOVA followed by 
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Fishers LSD post hoc test for multiple groups.  The chi-square test was applied for qualitative 
variables.  Correlations were evaluated by Pearson correlation analysis.  Statistical significance was 
set at p ≤ 0.05. 
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RESULTS 
Biochemical, Clinical Parameters and Final Diagnosis of Patients Included in the Study  
Biochemical and clinical characteristics of the 111 patients who underwent surgery for unilateral 
excess aldosterone production included in the present study are reported in Table 3.   
Based on the four “corners” criteria reported previously, PA patients were sub-classify in according 
to their final diagnosis as APA, Bilateral form (BAH) being PAC and ARR still elevated after 
adrenalectomy and, BP Not Cured (BP-NC) when there was biochemical PA picture resolution 
though not normalization of hypertension after surgery.   
Of 111 patients, 94 were diagnosed as APA (n=94), eight patients were diagnosed as BAH and five 
were diagnosed as BP-NC.  For four patients Follow Up (FU) data were not available and so they 
were excluded from the study.   
All patients showed high aldosterone concentration, ARR and BP values at baseline (Table 3).  
After adrenalectomy APAs exhibited a fall of BP despite a reduction of the number of 
antihypertensive drugs along with normalization of serum K
+
 and ARR.  BP-NC patients displayed 
a decrease in aldosterone concentration and increase in PRA but BP levels still elevated.  BAH 
patients did not show a reduction in PAC and still presented high ARR at FU (Table 3).  
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Flow Chart of the patients included and excluded in the study 
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Table 3.  Biochemical and clinical characteristics of 111 PA patients included in the study 
Diagnosis 
 
 
Biochemicals 
APA 
(n=94) 
BAH 
(n=8) 
BP Not Cured 
(n=5) 
p 
Adrenalectomy Before After Before After Before After  
Sex (M/F, %) 52/48  75/25  40/60  NS 
Age (yrs) 49±1  55±4  63±5  .01
b
 
BMI (kg/m2) 27.4±0.5 26.9±0.5 28.1±1.1 27.9±1.2 31.0±3.8 28.7±3.3 NS 
SBP (mmHg) 155±2 131±1 152±4 142±4 170±8 150±6 ≤.02
d,e
 
DBP (mmHg) 94±1 83±8 94±2 90±4 84±5 80±7 ≤.03
d,e
 
K
+
 (mmol/L) 3.5±0.1 4.3±0.04 3.5±0.3 3.9±0.2 3.8±0.4 4.3±0.5 .005
d
 
PAC (ng/dl) 27.8±1.9 11.1±0.7 24.6±3.6 22.0±2.9 24.4±3.8 8.9±1.7 ≤.002
d,f
 
captoPAC 
(ng/dl) 
22.9±3.3 6.1±0.6 14.7±2.7 18.8±3.9 9.7 (n=1) 7.3 (n=1) ≤.001
d
 
PRA (ng/ml*h) 0.4±0.03 1.4±0.2 0.6±0.2 1.3±0.5 0.6±0.2 0.7±0.4 ≤.05
a
 
captoPRA 
(ng/ml*h) 
0.6±0.1 2.8±0.9 1.1±0.2 1.9±0.8 0.6±0.1 0.2 (n=1) NS 
ARR 108.2±8.7 14.8±1.7 81.1±24.6 42.5±19.8 61.3±26.4 20.2±5.8 ≤.001
d
 
Cortisol 
(nmol/L) 
325.3±32.1 338.5±16.9 330.0±66.4 312.1±34.9 246.7(n=1) 320.0±7.6 NS 
captoCortisol 
(nmol/L) 
357.7±30.4 190.1±16.0 246.7±10.7 240.0±50.1 254 (n=1) 243 (n=1) NS 
Drugs 
(numbers) 
2.2±0.2 1.2±0.1 2.3±0.6 2.3±0.5 2±1.2 NA ≤.03
d,f
 
APA, Aldosterone-Producing Adenoma; BAH, Bilateral Hyperplasia; SBP, Sistolic Blood Pressure; 
DBP, Diastolic Blood Presure; PAC, Plasma Aldosterone Concentration; captoPAC, PAC after 
captopril; PRA, Plasma Renin Activity; captoPRA, PRA after captopril; ARR, Aldosterone-Renin 
Ratio; captoCortisol, Cortisol after captopril; Drugs numbers, numbers of drugs before 
adrenalectomy. NA, Not Available. Mean ± SE.  
a 
= APA vs BAH before adrenalectomy; 
b 
=APA vs Not Cured before adrenalectomy; 
c 
=BAH vs 
Not Cured before adrenalectomy. 
d 
= APA vs BAH after adrenalectomy; 
e 
=APA vs Not Cured after 
adrenalectomy; 
f 
=BAH vs Not Cured after adrenalectomy.  
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CYP11B2/CYP11B1 Steroidogenic Immuno-Phenotype Patterns  
Ninety-four adrenal glands from PA patients diagnosed as APA were processed to double IHC for 
CYP11B2 and CYP11B1.  Five major patterns based on CYP11B2/CYP11B1 immunostaining 
were identified.  Pattern 1 comprises adenomas with uniform CYP11B2 staining and CYP11B1 
staining in the zona fasciculata (ZF) of the adjacent normal adrenal gland (n=15, 16%) (figure 5, 
panels 1-A-B).  Pattern 2 includes adenomas with a diffuse CYP11B2 staining but multiple cells 
positive for CYP11B1 inside the adenoma (figure 5, panels 2-C-D) (n=43, 46%).  To evaluate the 
co-expression of CYP11B2 and CYP11B1 triple IF for CYP11B2/CYP11B1/17α-hydroxylase was 
performed and, in pattern 2, some cells inside the adenoma showed co-expression of 
CYP11B2/CYP11B1 (figure 6).  Pattern 3 is represented by adenomas that do not express 
CYP11B2 but CYP11B1 and clusters of sub-capsular cells positive for CYP11B2 (n=2, 2%) (figure 
5, panels 3-E-F).  Pattern 4 identifies adrenal glands with no evidence of an adenoma; in these 
samples merely multiple clusters of sub-capsular CYP11B2 cells were present (n=24, 25%) (figure 
5, panels 4-G-H).  Patter 5 includes multi-nodular adrenal cortex positive prevalently for CYP11B1 
with clusters of sub-capsular CYP11B2 cells (n=10, 11%) (figure 5, panels 5-I-L).   
Seventeen adrenal glands from patients not diagnosed as APA by the four “corners” criteria were 
distributed into 5 patterns as follows (the number of cases shown in parentheses): BAH (pattern 1, 
n=1; pattern 3, n=3; pattern 4, n=1; pattern 5, n=3); BP-NC (pattern 3, n=5) (p≤.001). 
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Figure 5.  CYP11B2/CYP11B1 steroidogenic patterns 
Examples of histological expression of CYP11B2 (brown) and CYP11B1 (green) in APA. Each line 
represent images at different magnification of the same adrenal gland classified in the five patterns.  
Nucleus are stained with HE. 
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Figure 6.  Triple Immunofluorescence for CYP11B2, CYP11B1 and 17α-hydroxylase 
Example of triple immunofluorescence for CYP11B2, CYP11B1, and 17α-hydroxylase in the same 
adrenal gland from a patient classified as pattern 2. Upper panels show images of triple 
immunofluorescence for CYP11B2, CYP11B1, and 17α-hydroxylase at the same magnification 
[10X]. Lower panels are the merged image of CYP11B2 (red) and 17α-hydroxylase (green), 
CYP11B2 (red) and CYP11B1 (green), CYP11B2 (green) and 17α-hydroxylase (red), respectively. 
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Sixteen NAGs were processed for CYP11B2 and double CYP11B2/CYP11B1 IHC.  These adrenals 
showed the expected strong CYP11B2 immunosignal limited to clusters of sub-capsular Zona 
Glomerulosa (ZG) cells whereas CYP11B1 staining was present predominantly in ZF cells (figure 
7).   
 
 
Figure 7.  Example of Double IHC for CYP11B2 and CYP11B1 in the Normal Adrenal Gland 
Examples of histological expression of CYP11B2 (brown) and CYP11B1 (green) in Normal 
Adrenal Gland. Panels A-B-C are images at different magnification of the same adrenal gland. 
Nucleus are stained with HE. 
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Clinical Characteristics of APA Patients in Steroidogenic Patterns Before Adrenalectomy 
 
The clinical characteristics of APA patients in patterns before adrenalectomy are shown in Table 4.   
We observed that patients classified into patterns 1 and 2 were younger and had lower BMI than 
patients in patterns 3, 4 and 5 (46±3 vs 54±6. p≤.03 and 26.7±0.8 vs 30.2±3.0. p≤.03).  Of interest, 
pattern 2 showed prevalence of female gender (64%; p=.005), higher PAC (32.5±3.2) and higher 
ARR (123.3±14.7) compared to the other patterns.  Two cases were classified as pattern 3, they 
expressed higher K
+
 than cases in patterns 1, 2 and 5 (4.5±0.4 vs 3.5±0.2. p≤.03) along lower PAC 
(17.4±2.5).  When captopril stimulation was performed, aldosterone production decreased more in 
patterns 4 and 5 than in patterns 1 and 2 (13.9±4.3 vs 24.8±4.7). 
 
We performed the genotype analysis for the most common KCNJ5 mutations (G151R, L168R and 
T158A)
95
 in 56 APA cases of the cohort of 94 adrenal glands previously diagnosed as APAs.  This 
analysis revealed that 32% of those patients presented one of the mutations in the K
+
 channel 
GIRK4.  Interestingly, nearly 72% of the patients with a known KCNJ5 mutation was classified into 
pattern 2 (p=.012). 
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Table 4.  Clinical characteristics at baseline of patients included in patterns. 
Pattern 1 (n=15) 2 (n=43) 3 (n=2) 4 (n=24) 5 (n=10) p 
Sex (M/F, %) 80/20 33/67 50/50 58/42 80/20 .005 
Age (yrs) 46±3 46±2 53±13 55±2 54±3 ≤.03
a
 
BMI (kg/m2) 27.9±0.9 25.5±0.7 31.8±6.2 29.4±0.9 29.3±1.9 ≤.03
b
 
SBP (mmHg) 157±8 154±3 145±5 155±5 163±9 NS 
DBP (mmHg) 95±5 93±2 88±3 94±3 99±7 NS 
K
+
 (mmol/L) 3.5±0.1 3.4±0.1 4.5±0.4 3.7±0.1 3.4±0.3 ≤.03
c
 
PAC (ng/dl) 23.5±2.2 32.5±3.2 17.4±2.5 23.5±2.7 23.4±7.5 NS 
captoPAC 
(ng/dl) 
21.8±3.5 27.8±5.8 NA 17.3±4.1 10.5±4.4 NS 
PRA 
(ng/ml*h) 
0.43±0.11 0.38±0.05 0.30±0.10 0.30±0.05 0.37±0.13 NS 
captoPRA 
(ng/ml*h) 
0.91±0.37 0.47±0.06 NA 0.25±0.07 1.01±0.50 NS 
ARR 94.4±15.3 123.3±14.7 68.4±31.1 95.9±14.4 90.5±23.7 NS 
Cortisol 
(nmol/L) 
288±69 340±47 NA 306±71 320±95 NS 
captoCortisol 
(nmol/L) 
481±69 372±40 NA 237±26 280±21 0.02
d
 
Drugs 
(numbers) 
2.1±0.3 2.4±0.2 1.0 2.1±0.3 2.3±0.6 NS 
 
SBP, Sistolic Blood Pressure; DBP, Diastolic Blood Presure; PAC, Plasma Aldosterone 
Concentration; captoPAC, PAC after captopril; PRA, Plasma Renin Activity; captoPRA, PRA after 
captopril; ARR, Aldosterone-Renin Ratio; captoCortisol, Cortisol after captopril; Drugs numbers, 
numbers of drugs before adrenalectomy. NA, Not Available. Mean ± SE.  
a 
Pattern 4 vs 1, 2. Pattern 2 vs 5. 
b 
Pattern 2 vs 3,4,5.  
c 
Pattern 3 vs 1, 2, 5.  
d 
Pattern 1 vs 4.  
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Morphometric Analysis of APAs, Clusters and Nodules 
Immunoreactivity for CYP11B2 and CYP11B1 was evaluated according to the modified version of 
the McCarty H-score as specified in the Method section.  In each adrenal gland adenomas, clusters 
and nodules of aldosterone-producing cells were assessed semi-quantitatively for both CYP11B2 
and CYP11B1 staining.   
H-score quantification for CYP11B2 and CYP11B1 in patterns is reported in Table 5.   
The CYP11B2 H-score in APAs resulted higher in pattern 1 and 2 than in pattern 3 (528±131; 
571±55 vs 16±13. p=.04).  The H-score analysis for CYP11B2 positive clusters showed that NAG 
clusters presented H-score similar to H-score obtained in clusters of pattern 4 (349±56 and 377±82) 
and higher (165±32, p≤.020) than that of clusters in pattern 2.   
The analysis of the total CYP11B2 H-score in patterns and NAG (Table 5) showed that patterns 1 
and 2 presented CYP11B2 H-score two fold higher than pattern 4 and NAG (p≤.05).  Interestingly, 
NAG and adrenal glands classified in pattern 4 showed similar CYP11B2 H-score (377±82 and 
349±56).   
Concerning total CYP11B1 total H-score, pattern 2, in which the adenoma was double stained for 
the two steroidogenic enzymes, showed a total higher score than the CYP11B1 positive adenoma of 
pattern 3, and the multinodular adrenals of pattern 5 (325±32 vs 218±185 and 117±19, respectively. 
p≤.01).  
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Table 5.  CYP11B2/CYP11B1 H-score values for NAG and pattern of PA patients 
CYP11B2 H-score (A.U.) 
 
Pattern 1  
(n=15) 
Pattern 2 
(n=43) 
Pattern 3 
(n=2) 
Pattern 4 
(n=24) 
Pattern 5 
(n=10) 
NAG 
(n=16) 
p 
APA 528±131 571±55 16±13 - - - 0.038
a
 
Clusters 
216±55 
(n=10) 
165±32 
(n=24) 
95 (n=1) 377±82 
215±36 
(n=8) 
349±56 ≤.020
b
 
Nodules - 
4.6±4.5 
(n=2) 
- - 6.7±2.7 - NS 
Total B2  672±141 663±59 65±62 377±82 179±40 349±56 
≤.02
b, c 
≤.05
a, d
 
CYP11B1 H-score (A.U.) 
 
Pattern 1  
(n=15) 
Pattern 2 
(n=43) 
Pattern 3 
(n=2) 
Pattern 4 
(n=24) 
Pattern 5 
(n=10) 
NAG 
(n=16) 
p 
APA 199±61 295±33 185±151 - - - NS 
Clusters 
60±16 
(n=10) 
50±10 
(n=24) 
15 (n=1) 91±18 
83±17 
(n=8) 
67±12 .05
e
 
Nodules - 
23±17 
(n=2) 
- - 45±9 - NS 
Total 240±60 325±32 218±185 91±18 117±19 67±12 ≤.01
b,
 
f, g
  
number 
of  
clusters 
2.7±0.8 2.2±0.5 1 (n=1) 7.2±1.4 3.3±0.9 9.6±2.0 
≤.02
g
 
≤.001
b
 
.029
h
 
 
AU, Arbitrary Units. Mean±SE. 
a 
Pattern 2 vs 3 
b 
Pattern 2 vs 4 and NAG 
c 
Pattern 5 vs 1 and 2 
d 
Pattern 1 vs 3, 4 and NAG 
e 
Pattern 2 vs 4 
f  
Pattern 2 vs 5 
g 
Pattern 1 vs 4 and NAG 
h 
Pattern 5 vs NAG 
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The CYP11B2 H-score and Aldosterone Production Before Adrenalectomy 
We hypothesized that the H-score for CYP11B2 reflected the aldosterone production.  Hence, we 
investigated if CYP11B2 or CYP11B1 score in APA, nodules, clusters or the total score correlated 
with the AVS characteristics of patients (Table 6, figure 8).  To this aim the correlation of the 
CYP11B2 and CYP11B1 H-score with PAC in the APA, contralateral side and the inferior vein 
cava were analysed.   
The CYP11B2 H-score detected in APAs correlated directly with PAC (r=0.388, p=.002) and 
aldosterone concentration in the inferior vein cava (IVC) (r=0.454, p=.006) (figure 8).  By contrast 
the CYP11B1 H-score did not correlate with cortisol production.   
The CYP11B2 H-score in the clusters showed a direct correlation with aldosterone concentration in 
the adrenal vein when this value was normalized for the aldosterone in IVC (r=0.542, p=.001) 
(figure 8).  Interestingly, even nodules prevalently stained for CYP11B1, showed a CYP11B2 H-
score that was highly correlated with the ARR (r=0.815, p=.002), albeit not with plasma cortisol 
level.   
Total CYP11B2 H-score was evaluated from the sum of the CYP11B2 staining intensity in all the 
aldosterone producing structures, including APA, clusters and nodules.  It showed a direct 
correlation with PAC (r=0.335, p=0.002), aldosterone in IVC (r=0.338, p=.0016) and the ratio of 
the aldosterone in the dominant side normalized for the aldosterone concentration in IVC (r=0.492, 
p=0.023) (figure 8).  
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Table 6.  Correlation of CYP11B2/CYP11B1 H-score and biochemical parameters  
        H-score 
 
 
 
Biochemicals  
CYP11B2 
APA 
CYP11B1 
APA 
CYP11B2 
Clusters 
CYP11B1 
Clusters 
CYP11B2 
Nodules 
CYP11B1 
Nodules 
CYP11B2 
Total 
CYP11B1 
Total 
PAC .388** .144 .090 -.049 .368 .298 .335** .166 
Capto-PAC .361 .159 -.150 -.210 .350 .483 .297 .152 
PRA .084 -.097 -.141 -.117 -.357 -.146 .066 -.043 
ARR .143 .196 .039 -.066 .815** .466 .140 .191 
PCC .175 -.265 .012 .189 -.603 -.260 .192 -.147 
Aldo IVC .454** .035 -.131 -.262 -.264 -.079 .338* .040 
Aldo APA .117 .231 .542** .554** .094 -.245 .458* .293 
LI .112 -.019 -.019 -.015 .559 .237 .148 .198 
CL Index -.222 -.233 .182 .128 -.253 -.294 -.099 -.177 
RAS Index -.077 -.094 .050 .113 .533 .256 .044 .024 
PAC, Plasma Aldosterone Concentration; Capto-PAC, PAC after Captopril stimulation; PRA, 
Plasma Renin Activity; ARR, Aldosterone-Renin Ratio; PCC; Plasma Cortisol Concentration; Aldo 
IVC, [Aldosterone] in the inferior vein cava; Aldo APA, [Aldo]/[Aldo IVC] in the adrenal vein of 
APA side; LI, Lateralization Index, (aldosterone/cortisol APA adrenal vein)/(aldosterone/cortisolcontralateral 
adrenal vein); CL Index, (aldosterone/cortisol contralateral  adrenal vein)/(aldosterone/cortisol IVC); RAS Index, 
(aldosterone/cortisol APA adrenal vein)/(aldosterone/cortisol IVC).  ** p≤.01;* p≤.05  
 
Figure 8.  Correlations of CYP11B2 H-score with the aldosterone production 
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Steroidogenic Patterns and H-score do not Predict the Biochemical Profile After 
Adrenalectomy  
After adrenalectomy, the biochemical profiles of the APA patients classified into steroidogenic 
patterns did not differ significantly among patterns.   
After adrenal surgery all PA patients showed the decrease of aldosterone concentration to normal 
level and the expected increase of plasma renin activity (PRA).  However, no clinical differences 
were found among steroidogenic patterns.   
Concerning the H-score, CYP11B2 expression in clusters correlated with PRA (r=0.386, p=.004) 
and CYP11B2 score in nodules correlated inversely with plasma K
+
 levels (r=-0.844, p=.001).   
To further understand if different H-scores immuno-phenotypes may predict different outcomes 
after surgery we performed IHC and measurement of CYP11B2 and CYP11B1 H-score also for the 
eight patients, who were retrospectively diagnosed as BAH at follow up and the five patients 
diagnosed as BP-NC.  In particular, BAH adrenals presented very heterogeneous immunostaining 
profiles: one case showed an adenoma positive for CYP11B2, three cases displayed an adenoma 
prevalently positive for CYP11B1, one case showed no adenoma but multiple clusters of sub-
capsular CYP11B2 positive and three patients had multiple nodules positive for CYP11B1 and 
CYP11B2 cell clusters.  BP-NC patients were all classified as pattern 3 (i.e. adenomas prevalently 
positive for CYP11B1).   
Quantification of H-scores in BAH and BP-NC adrenals are reported in Table 7.   
No correlation among biochemicals of BAH patients and BP-NC patients and CYP11B2 and 
CYP11B1 H-score were found, either at baseline or follow up. 
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Table 7.  CYP11B2/CYP11B1 H-score values for BAH, NAG and BP-NC patients 
 
CYP11B2 H-score (A.U.) 
 BAH (n=8) BP-NC (n=5) NAG (n=16) p 
APA 11±5 (n=4) 43±27 - NS 
Clusters 423±121 188±38 349±56 NS 
Nodules 6.5±6 (n=3) - - NS 
Total B2 378±117 194±68 349±56 NS 
CYP11B1 H-score (A.U.) 
 BAH (n=8) BP-NC (n=5) NAG (n=16)  
APA 70±36 (n=4) 439±162 - NS 
Clusters 122±48 60±22 67±12 NS 
Nodules 44±21 (n=3) - - NS 
Total 158±46 487±149 67±12 <.01
a
 
Num clusters 6.2±1.9 2.2±0.6 9.6±2.0 NS 
 
BAH, Bilateral Hyperplasia; BP-NC, Blood Pressure Not Cured; NAG, Normal Adrenal Gland; 
Num clusters: number of CYP11B2 positive clusters. Mean±SE.  
a  
BP-NC vs NAG and BAH 
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DISCUSSION 
After 60 years from Conn’s first description of APA, only in the last 10 years great strides have 
been made in our understanding of the genetics and pathophysiology of PA in spite of more than 
nine thousand studies published on the topic.  The current Endocrine Society guidelines for the 
detection of PA
23
 and the ‘Four Corners Criteria’
44
 are key for the correct diagnosis of 
hyperaldosteronism.  However, until only recently the histopathology diagnostic criteria for the 
assessment of the adrenals excised from patients with PA lagged far behind.  When a yellow, well-
circumscribed tumor is found, it seemed reasonable to assume that this entailed an APA.  However, 
standard histological staining by itself provides no information on the functional phenotype, and 
therefore whether the nodule is responsible for the over-production of aldosterone remains 
ambiguous.  The only way to identify aldosterone-producing cells is the detection of the final 
enzymes involved in the biosynthesis of aldosterone, i.e. aldosterone synthase.  This steroidogenic 
enzyme, encoded by the CYP11B2 gene, shares 93% of the aminoacidic sequence with CYP11B1 
gene, the enzyme involved in the synthesis of cortisol.  This is the reason for the difficulty in 
generation of specific and not cross-reacting antibodies.  Only recently, prof. Gomez-Sanchez from 
the University of Mississippi Medical Center (Jackson, USA) and prof. Nishimoto from the Keio 
University (Tokyo, Japan)
53,59
 achieved this goal generating antibodies against CYP11B2 and 
CYP11B1.  This is one of  the most important advances in the study of the adrenal gland in the last 
years, and is expected to improve our understanding of the adrenal disorders, as PA.
96
   
We benefited from the antibodies developed in the laboratory of prof. Gomez-Sanchez and, in 
collaboration with him, we identified the steroidogenic immunophenotypes of the adrenal glands in 
a large cohort of PA patients. 
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Identification of Five Steroidogenic Patterns in PA Adrenals 
By analysing 111 adrenal glands removed from PA we identified five different immunophenotypes.  
We arbitrarily termed as “patterns”, numbering consecutively from 1 to 5.  Patterns 1 and 2 
comprised the adenomas that could be named “classical APA” because the cases presented a well-
circumscribed tumor positively stained for CYP11B2 (figure 5).  Differently from pattern 1, pattern 
2 showed a mixture of cells positive for CYP11B2 or CYP11B1, with some cells co-expressing 
both the markers as confirmed by triple immunofluorescence for CYP11B2, CYP11B1 and the ZF 
enzyme CYP17α (figure 6).  This latter gene encodes for the 17α–hydroxylase, an enzyme 
expressed in the zona fasciculata and in the zona reticularis of the adrenal gland.  Co-expression of 
CYP11B2 and CYP17α clearly indicates that those cells present the enzyme machinery needed to 
produce both aldosterone and cortisol, and therefore that they exhibit a mixed phenotype with ZG 
and ZF characteristics.   
Clinically, both patterns (in particular pattern 2) are characterized by a high percentage of female 
and younger patients, with lower BMI than patients of any other pattern (patterns 3, 4 and 5).  The 
results of our study  are in agreement with the results of a previous study by Azizan,
97
 which 
reported that 58% of female APAs were characterized by a ZF transcriptional profiles, suggesting a 
dimorphism for histopathology of APA.  
The other patterns (i.e. patterns 3, 4 and 5) showed “non classical” aspect of APA: pattern 3, 
displayed negative staining for CYP11B2 in the main nodule but strong positivity for CYP11B1, 
with aldosterone-producing cells confined to clusters in the sub-capsular region (figure 5); pattern 5 
showed different nodules prevalently stained for CYP11B1 with few cells positive for CYP11B2 
and CYP11B2 cell clusters (figure 5), and pattern 4  was characterized by CYP11B2 cell clusters 
with no nodule(s) (figure 5).   
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Aldosterone and Cortisol Production in the Steroidogenic Patterns Before Adrenalectomy 
After identification of the CYP11B2 and CYP11B1 steroidogenic patterns of a large cohort of 
adrenal glands excised for PA, we wondered if aldosterone and cortisol production differs among 
them.   
It was expected that the tumors containing only CYP11B1-positive cells (i.e. pattern 3) were 
cortisol-producing and non-hyperfunctioning but, on the contrary, cortisol levels did not differed 
between patterns.  Furthermore, unexpectedly the absence of an aldosterone-producing tumor in 
patterns 3, 4 and 5 was not associated with lower aldosterone production than patterns 1 and 2, 
showing PAC similar to those of classical APAs.  Hence, it is concevaible that aldosterone 
production in patterns 3, 4 and 5 could be due to the activity of CYP11B2 positive cell clusters that, 
therefore, could play a major role in the excess aldosterone production in PA.   
Clusters of cells expressing CYP11B2 were first identified and named aldosterone-producing cell 
clusters (APCCs) by Nishimoto’s group in 2010,
59
 but their role in autonomous aldosterone 
production and potentially PA remains unknown.  In NAGs APCCs are located just below the 
adrenal capsule and prolonged into cortisol-producing cells, as described in the present study and 
previous reports.
59,78,82
  Considering the low circulating renin levels in PA patients, the aldosterone 
production by APCC was deemed to be renin-independent.  However, the presence of APCC in 
normal adrenal tissue indicates that APCC are not markers of excess aldosterone production.  
Whether APCC may represent a precursor of the APA is an intriguing question.  Nishimoto and 
Rainey’s at the University of Michigan, by analysing the transcriptome profile of APCC in a series 
of normal adrenals, detected the presence of CACNA1D and ATP1A1, two somatic mutations that 
are recurrently observed in APA population.
98
  These mutations are known to cause aldosterone 
over-production in the APA,
99
 thereby suggesting a role for APCC in the development of 
aldosterone-producing tumors, and also explaining the similar PAC value found in the patients with 
patterns 3, 4 and 5. 
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The Steroidogenic Patterns identify Different KCNJ5 Genetic Profile 
Somatic mutations of the G protein-activated inwardly rectifying K
+
 channel Kir3.4, encoded by the 
KCNJ5 gene, were discovered by Choi et al. in 2011
32
 and represented a major advance in the 
understanding of the pathogenesis of PA.  The overall prevalence of KCNJ5 mutations in APA 
population is very high (around 43%)
100
 and therefore, the comprehension of the molecular 
mechanisms triggered by KCNJ5 and putatively involved in the aldosterone-overproduction is of 
primary interest.   
KCNJ5 mutations are located in, or close to, the selectivity filter,
101
 a highly conserved region 
within this family of channels that allows the selective transport of K
+
 over other cations.
32
  
Mutations of Kir3.4 in in vitro experiments resulted in loss of channel selectivity with increase in 
intracellular sodium, membrane depolarization, and increase in mobilization of calcium, resulting in 
enhanced expression of the CYP11B2 enzyme and synthesis of aldosterone.
101
  
The results of our study showed an interesting correlation between the histological pattern and the 
genotype.  KCNJ5 mutations were detected mostly in adrenal glands with a nodule expressing a 
mixture of CYP11B1 and CYP11B2 positive cells, classified as pattern 2.  This is in agreement 
with a previous study conducted by Azizan
102
 that reported that KCNJ5 mutated tumors presented 
with a ZF genetic profile associated with a tumor composed mainly of large, CYP11B1 or 
CYP11B2 and CYP17α positive cells. 
A recent meta-analysis of KCNJ5 mutations in APA patients
100
 reported that the presence of 
mutations in the KCNJ5 gene identify patients with higher PAC than wild type.  Even though we 
observed an increased PAC in patients with KCNJ5 mutated tumors, compared to the wild type, this 
increase was not significant.  Such a disagreement could be explained by the small number of 
genotyped patients in our cohort (n=56) that did not permit to reach the statistical significance.  It is 
also true that our wild-type tumors are probably a heterogeneous group of adenomas carrying other 
somatic mutations (not investigated in this study) that could increase aldosterone synthesis (e.g. 
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ATP1A1, ATP2B3 or CACNA1D)
84,85
 and other so far unidentified genes that may be involved in 
regulating and over-producing aldosterone in APAs.   
H-score Reflects the Aldosterone Production before Adrenalectomy 
Immunohistochemistry (IHC) is one of the most common used technique in the research 
laboratories, due to its not expensive approach, feasibility of the procedures and warranty of 
unequivocally identifying the presence of markers in the tissue.  The antibodies should be specific 
and not cross-reacting with epitopes similar to the antigens against which the antibodies were 
raised.  Moreover, an intense and definite chromatic reaction is expected to be developed where the 
antigen is localized, and the staining intensity should be easily measurable to investigate if specific 
markers recognized by the antibodies correlate with clinical or biochemical variables.   
The availability of the novel antibodies for CYP11B2 and CYP11B1 specific for the target enzymes 
prompted us to develop a quantification system that permits to quantify  the intensity of the 
immunostaining.  The most used quantification scoring system for IHC markers is the McCarty’s 
H-score system
80
 in which the percentage of the stained cells is multiplied by a factor ranging from 
0 to 3 to reflect the intensity of cell immunostaining.  H-score, which has been used by oncologists 
for years, recently has been also proposed as a tool to investigate the steroidogenesis in the adrenal 
gland tumors.  The main drawback of H-score is the staining intensity operator-dependent 
assessment, which accounts for the inter-assay variability.  Hence, in the present study we 
developed a modified version of the McCarty H-score to overcome this problem by measuring 
directly the staining intensity using an observer-independent PC-assisted method specifically 
created in our laboratory with ImageJ software (detailed explanation in the Methods section).  To 
avoid missing information on the aldosterone synthesis in the whole adrenal gland, in our study, we 
quantified H-score for each potential aldosterone-producing structure stained with CYP11B2, 
including APCCs, APA and nodules.  The results of our study showed that CYP11B2 score in APA 
and clusters reflected the aldosterone levels before adrenalectomy.  A correlation between the 
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classic H-score staining of CYP11B2 and CYP11B1 limited to the adenoma was searched 
previously by three independent groups, but it was found only when the score was normalized for 
the tumor area or volume.
76,81,82
  Hence, the results of our study showed that this modified version 
of H-score provides more accurate information on the functional activity of CYP11B2 in the 
adrenal gland and that there is the need to analyse all the structures involved in aldosterone 
production to obtain a correct clinical correspondence. 
By contrast, CYP11B1 H-score did not correlate with the cortisol production, likely because we 
assessed the CYP11B1 expression in structures that are involved in the aldosterone, not cortisol 
synthesis, thereby excluding zona fasciculata cells.  Whether CYP11B1 H-score evaluated in the 
whole adrenal gland may provide information on the cortisol production remains unknown.   
The Steroidogenic Patterns and H-score do not Predict the Biochemical Outcome of PA 
Patients 
We investigated the biochemicals and BP correction outcome of unilateral adrenalectomy among 
111 patients operated for PA in three referral centers for hypertension in Italy.  As expected, at 
follow up all APA cases exhibited a decrease in aldosterone and an increase in renin and K
+
 levels, 
but a surprising finding was that these patients, although showing different steroidogenic patterns, 
did not show different biochemical pictures after surgery, suggesting that PA disease involved 
several histological appearances but they are equally resolved by the resection of the aldosterone 
over-producing adrenal gland.  In addition, when we studied the correlations among the staining 
intensity of CYP11B2 and CYP11B1 of the adrenal glands with biochemical or clinical variables of 
patients at follow up, no correlation were found.  Hence, in our hands H-score was not a predictive 
tool for the biochemical outcome of adrenalectomized patients. 
Furthermore, when we analysed the adrenal glands from patients who underwent surgery because 
unilateral over-production of aldosterone was found at AVS, but were diagnosed as bilateral 
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hyperplasia (BAH) retrospectively, we found an high variability of steroidogenic immuno-
phenotypes, making difficult to identify a pattern that is characteristic for BAH.   
Of interest, when we processed the adrenal glands of five patients who successfully resolved the 
biochemical PA picture with adrenalectomy, but still presented elevated BP levels at follow up, they 
showed histological characteristics of patients classified as pattern 3 (i.e. CYP11B1 positive 
adenoma).  This finding suggests that pattern 3 is the pattern that characterizes the patients who take 
advantage of adrenal surgery for biochemical, but still require medications to control BP levels.  
Hence, patients who show steroidogenic pattern 3 at histology would require strict follow-up after 
surgery to achieve optimal blood pressure control.   
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CONCLUSIONS  
The present study revealed that in a large cohort of PA patients who underwent surgery on the basis 
of the AVS the histological profile of the removed adrenal gland was very heterogeneous. 
Five different steroidogenic patterns can be identified with the use of recently developed 
monoclonal antibodies against the aldosterone synthase and the 11β-hydroxylase.  The 
steroidogenic patterns with a “classical APA” appearance (i.e. patterns 1 and 2) pinpoint patients 
with biochemical and genetic characteristics that are different from those entailing “non canonical” 
APA (i.e. patterns 3, 4 and 5).   
The modified version of the McCarty H-score developed in our laboratory was observer-
independent and took into account not only staining intensity, but also the surface of the stained 
structures.  Moreover, H-score was assessed not only in APA but also in APCCs and nodules, 
thereby providing accurate information on the aldosterone synthesis in the whole adrenal gland.  
Hence, the H-score developed by our group could be more accurate in estimating aldosterone 
production than the classical H-score.   
After adrenalectomy, the steroidogenic patterns and the modified H-score failed to predict different 
clinical outcomes for either APA or BAH patients.  However, pattern 3 was mostly found in 
patients who took advantage of adrenal surgery for correction of the biochemical picture, but did 
not reach optimal BP control.   
In conclusion, based on the results of our study we would like to propose a novel classification of 
surgical-correctable PA into CYP11B2 and CYP11B1 steroidogenic patterns that could be a useful 
diagnostic tool to localize aldosterone production sites in the excised adrenal gland and contribute 
to provide better understanding in the pathophysiology of PA disease.
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